$NTLA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Intellia Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Intellia Therapeutics, Inc.. Get notifications about new insider transactions in Intellia Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 11 2017 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Sell | S | 16.77 | 30,000 | 502,992 | 3,699,788 | 3.7 M to 3.7 M (-0.80 %) |
| Jun 05 2017 | NTLA | Intellia Therapeut ... | DORSA CAROLINE | Director | Grant | A | 12.42 | 5,000 | 62,100 | 5,000 | 0 to 5 K |
| Jun 05 2017 | NTLA | Intellia Therapeut ... | KARSEN PERRY A | Director | Grant | A | 11.99 | 5,000 | 59,925 | 5,000 | 0 to 5 K |
| Jun 05 2017 | NTLA | Intellia Therapeut ... | Bell Graeme | EVP, Chief Financia ... | Grant | A | 12.37 | 8,400 | 103,938 | 8,400 | 0 to 8.4 K |
| Jun 05 2017 | NTLA | Intellia Therapeut ... | Rivera Jose E | EVP, General Counse ... | Grant | A | 12.03 | 8,400 | 101,075 | 8,994 | 594 to 9 K (+1,414.14 %) |
| Jun 05 2017 | NTLA | Intellia Therapeut ... | LEONARD JOHN M. | EVP, R&D | Grant | A | 12.09 | 600 | 7,254 | 8,400 | 7.8 K to 8.4 K (+7.69 %) |
| Jun 05 2017 | NTLA | Intellia Therapeut ... | LEONARD JOHN M. | EVP, R&D | Grant | A | 12.06 | 7,800 | 94,068 | 7,800 | 0 to 7.8 K |
| Jun 05 2017 | NTLA | Intellia Therapeut ... | Bermingham Nessan | President & CEO | Grant | A | 11.95 | 8,400 | 100,379 | 795,033 | 786.6 K to 795 K (+1.07 %) |
| May 19 2017 | NTLA | Intellia Therapeut ... | GORDON CARL L | Director | Option Exercise | A | 14.35 | 19,000 | 272,650 | 19,000 | |
| May 19 2017 | NTLA | Intellia Therapeut ... | DORSA CAROLINE | Director | Option Exercise | A | 14.35 | 19,000 | 272,650 | 19,000 | |
| May 19 2017 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 14.35 | 19,000 | 272,650 | 19,000 | |
| May 19 2017 | NTLA | Intellia Therapeut ... | KARSEN PERRY A | Director | Option Exercise | A | 14.35 | 19,000 | 272,650 | 19,000 | |
| Mar 13 2017 | NTLA | Intellia Therapeut ... | Atlas Venture Associates IX, L ... | 10% Owner | Sell | S | 14.06 | 5,504 | 77,410 | 0 | 5.5 K to 0 (-100.00 %) |
| Mar 13 2017 | NTLA | Intellia Therapeut ... | Atlas Venture Associates IX, L ... | 10% Owner | Sell | S | 13.85 | 15,628 | 216,432 | 5,504 | 21.1 K to 5.5 K (-73.95 %) |
| Mar 13 2017 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Sell | S | 14.06 | 5,504 | 77,410 | 0 | 5.5 K to 0 (-100.00 %) |
| Mar 13 2017 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Sell | S | 13.85 | 15,628 | 216,432 | 5,504 | 21.1 K to 5.5 K (-73.95 %) |
| Mar 07 2017 | NTLA | Intellia Therapeut ... | Novartis Institutes for BioMed ... | 10% Owner | Buy | J | 0.00 | 79,245 | 0 | 5,652,903 | 5.6 M to 5.7 M (+1.42 %) |
| Mar 07 2017 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Sell | J | 0.00 | 700,000 | 0 | 3,729,788 | 4.4 M to 3.7 M (-15.80 %) |
| Jan 10 2017 | NTLA | Intellia Therapeut ... | Heifner Nicole | SVP, Accounting | Option Exercise | A | 13.88 | 28,500 | 395,580 | 28,500 | |
| Jan 10 2017 | NTLA | Intellia Therapeut ... | Morrissey David V | SVP, Platform & Del ... | Option Exercise | A | 13.88 | 30,000 | 416,400 | 30,000 | |
| Jan 10 2017 | NTLA | Intellia Therapeut ... | Barnes Thomas M. | SVP, R&D eXtellia | Option Exercise | A | 13.88 | 50,500 | 700,940 | 50,500 | |
| Jan 10 2017 | NTLA | Intellia Therapeut ... | LEONARD JOHN M. | EVP, R&D | Option Exercise | A | 13.88 | 95,000 | 1,318,600 | 95,000 | |
| Jan 10 2017 | NTLA | Intellia Therapeut ... | Rivera Jose E | EVP, General Counse ... | Option Exercise | A | 13.88 | 115,000 | 1,596,200 | 115,000 | |
| Jan 10 2017 | NTLA | Intellia Therapeut ... | Bermingham Nessan | President & CEO | Option Exercise | A | 13.88 | 270,000 | 3,747,600 | 270,000 | |
| Jan 05 2017 | NTLA | Intellia Therapeut ... | Bell Graeme | EVP, Chief Financia ... | Option Exercise | A | 13.48 | 210,000 | 2,830,800 | 210,000 | |
| May 13 2016 | NTLA | Intellia Therapeut ... | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 873,475 | 0 | 0 | |
| May 13 2016 | NTLA | Intellia Therapeut ... | ORBIMED ADVISORS LLC | Director | Option Exercise | C | 0.00 | 2,857,143 | 0 | 0 | |
| May 13 2016 | NTLA | Intellia Therapeut ... | ORBIMED ADVISORS LLC | Director | Buy | P | 18.00 | 58,534 | 1,053,612 | 2,662,180 | 2.6 M to 2.7 M (+2.25 %) |
| May 13 2016 | NTLA | Intellia Therapeut ... | ORBIMED ADVISORS LLC | Director | Buy | P | 18.00 | 191,466 | 3,446,388 | 2,603,646 | 2.4 M to 2.6 M (+7.94 %) |
| May 13 2016 | NTLA | Intellia Therapeut ... | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 564,780 | 0 | 2,412,180 | 1.8 M to 2.4 M (+30.57 %) |
| May 13 2016 | NTLA | Intellia Therapeut ... | ORBIMED ADVISORS LLC | Director | Buy | C | 0.00 | 1,847,400 | 0 | 1,847,400 | 0 to 1.8 M |
| May 13 2016 | NTLA | Intellia Therapeut ... | Temasek Holdings (Private) Ltd | 10% Owner | Option Exercise | C | 0.00 | 490,527 | 0 | 0 | |
| May 13 2016 | NTLA | Intellia Therapeut ... | Temasek Holdings (Private) Ltd | 10% Owner | Buy | P | 18.00 | 300,000 | 5,400,000 | 790,527 | 490.5 K to 790.5 K (+61.16 %) |
| May 13 2016 | NTLA | Intellia Therapeut ... | Temasek Holdings (Private) Ltd | 10% Owner | Buy | C | 0.00 | 490,527 | 0 | 490,527 | 0 to 490.5 K |
| May 11 2016 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 761,905 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 1,333,333 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 3,809,524 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | C | 0.00 | 946,237 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 492,640 | 0 | 4,429,788 | 3.9 M to 4.4 M (+12.51 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 862,120 | 0 | 3,937,148 | 3.1 M to 3.9 M (+28.04 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 2,463,201 | 0 | 3,075,028 | 611.8 K to 3.1 M (+402.60 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Buy | C | 0.00 | 611,827 | 0 | 611,827 | 0 to 611.8 K |
| May 11 2016 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Option Exercise | C | 0.00 | 761,905 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,333,333 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Option Exercise | C | 0.00 | 3,809,524 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Option Exercise | C | 0.00 | 946,237 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Buy | C | 0.00 | 492,640 | 0 | 4,429,788 | 3.9 M to 4.4 M (+12.51 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Buy | C | 0.00 | 862,120 | 0 | 3,937,148 | 3.1 M to 3.9 M (+28.04 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Buy | C | 0.00 | 2,463,201 | 0 | 3,075,028 | 611.8 K to 3.1 M (+402.60 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | Atlas Venture Fund IX, L.P. | 10% Owner | Buy | C | 0.00 | 611,827 | 0 | 611,827 | 0 to 611.8 K |
| May 11 2016 | NTLA | Intellia Therapeut ... | Novartis Institutes for BioMed ... | 10% Owner | Option Exercise | C | 0.00 | 761,905 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Novartis Institutes for BioMed ... | 10% Owner | Option Exercise | C | 0.00 | 2,666,666 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Novartis Institutes for BioMed ... | 10% Owner | Option Exercise | C | 0.00 | 4,761,905 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Novartis Institutes for BioMed ... | 10% Owner | Buy | P | 18.00 | 277,777 | 4,999,986 | 5,573,658 | 5.3 M to 5.6 M (+5.25 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | Novartis Institutes for BioMed ... | 10% Owner | Buy | C | 0.00 | 492,640 | 0 | 5,295,881 | 4.8 M to 5.3 M (+10.26 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | Novartis Institutes for BioMed ... | 10% Owner | Buy | C | 0.00 | 1,724,240 | 0 | 4,803,241 | 3.1 M to 4.8 M (+56.00 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | Novartis Institutes for BioMed ... | 10% Owner | Buy | C | 0.00 | 3,079,001 | 0 | 3,079,001 | 0 to 3.1 M |
| May 11 2016 | NTLA | Intellia Therapeut ... | Haurwitz Rachel E. | Director | Option Exercise | C | 0.00 | 8,110,599 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Haurwitz Rachel E. | Director | Option Exercise | C | 0.00 | 270,352 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Haurwitz Rachel E. | Director | Buy | C | 0.00 | 5,244,234 | 0 | 5,593,846 | 349.6 K to 5.6 M (+1,500.02 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | Haurwitz Rachel E. | Director | Buy | C | 0.00 | 174,806 | 0 | 349,612 | 174.8 K to 349.6 K (+100.00 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | Caribou Therapeutics Holdco, L ... | 10% Owner | Option Exercise | C | 0.00 | 8,110,599 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Caribou Therapeutics Holdco, L ... | 10% Owner | Option Exercise | C | 0.00 | 270,352 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Caribou Therapeutics Holdco, L ... | 10% Owner | Buy | C | 0.00 | 5,244,234 | 0 | 5,593,846 | 349.6 K to 5.6 M (+1,500.02 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | Caribou Therapeutics Holdco, L ... | 10% Owner | Buy | C | 0.00 | 174,806 | 0 | 349,612 | 174.8 K to 349.6 K (+100.00 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | GORDON CARL L | Director | Option Exercise | C | 0.00 | 873,475 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | GORDON CARL L | Director | Option Exercise | C | 0.00 | 2,857,143 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | GORDON CARL L | Director | Buy | P | 18.00 | 58,534 | 1,053,612 | 2,662,180 | 2.6 M to 2.7 M (+2.25 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | GORDON CARL L | Director | Buy | P | 18.00 | 191,466 | 3,446,388 | 2,603,646 | 2.4 M to 2.6 M (+7.94 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | GORDON CARL L | Director | Buy | C | 0.00 | 564,780 | 0 | 2,412,180 | 1.8 M to 2.4 M (+30.57 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | GORDON CARL L | Director | Buy | C | 0.00 | 1,847,400 | 0 | 1,847,400 | 0 to 1.8 M |
| May 11 2016 | NTLA | Intellia Therapeut ... | Bermingham Nessan | President & CEO | Option Exercise | C | 0.00 | 675,883 | 0 | 0 | |
| May 11 2016 | NTLA | Intellia Therapeut ... | Bermingham Nessan | President & CEO | Buy | C | 0.00 | 437,019 | 0 | 786,633 | 349.6 K to 786.6 K (+125.00 %) |
| May 11 2016 | NTLA | Intellia Therapeut ... | BAKER BROS. ADVISORS LP | Option Exercise | C | 0.00 | 1,232,130 | 0 | 0 | ||
| May 11 2016 | NTLA | Intellia Therapeut ... | BAKER BROS. ADVISORS LP | Option Exercise | C | 0.00 | 101,204 | 0 | 0 | ||
| May 11 2016 | NTLA | Intellia Therapeut ... | BAKER BROS. ADVISORS LP | Buy | P | 18.00 | 179,531 | 3,231,558 | 976,214 | 796.7 K to 976.2 K (+22.53 %) | |
| May 11 2016 | NTLA | Intellia Therapeut ... | BAKER BROS. ADVISORS LP | Buy | P | 18.00 | 20,469 | 368,442 | 85,906 | 65.4 K to 85.9 K (+31.28 %) | |
| May 11 2016 | NTLA | Intellia Therapeut ... | BAKER BROS. ADVISORS LP | Buy | C | 0.00 | 796,683 | 0 | 796,683 | 0 to 796.7 K | |
| May 11 2016 | NTLA | Intellia Therapeut ... | BAKER BROS. ADVISORS LP | Buy | C | 0.00 | 65,437 | 0 | 65,437 | 0 to 65.4 K | |
| May 09 2016 | NTLA | Intellia Therapeut ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 18.00 | 23,529 | 423,522 | 23,529 | |
| May 09 2016 | NTLA | Intellia Therapeut ... | GORDON CARL L | Director | Option Exercise | A | 18.00 | 23,529 | 423,522 | 23,529 | |
| May 09 2016 | NTLA | Intellia Therapeut ... | Haurwitz Rachel E. | Director | Option Exercise | A | 18.00 | 23,529 | 423,522 | 23,529 | |
| May 09 2016 | NTLA | Intellia Therapeut ... | KARSEN PERRY A | Director | Option Exercise | A | 18.00 | 31,764 | 571,752 | 31,764 | |
| May 09 2016 | NTLA | Intellia Therapeut ... | DORSA CAROLINE | Director | Option Exercise | A | 18.00 | 15,176 | 273,168 | 15,176 |